Tag Archives: CDX-1401

June, 2016

  • 6 June

    Celldex Presents Positive Results from its Phase II Melanoma Study

    HAMPTON, N.J., June 04, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDX‑1401 and CDX‑301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex …